Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

被引：7

作者：

Kim, Youn H. ^{[1
]}

Whittaker, Sean ^{[2
]}

Horwitz, Steven M. ^{[3
]}

Duvic, Madeleine ^{[4
]}

Dummer, Reinhard ^{[5
]}

Scarisbrick, Julia J. ^{[6
]}

Quaglino, Pietro ^{[7
]}

Zinzani, Pier Luigi ^{[8
]}

Wolter, Pascal ^{[9
]}

Wang, Yinghui ^{[10
]}

Palanca-Wessels, Maria Corinna ^{[10
]}

Zagadailov, Erin ^{[11
]}

Trepicchio, William L. ^{[11
]}

Liu, Yi ^{[11
]}

Little, Meredith ^{[11
]}

Prince, H. Miles ^{[12
]}

机构：

[1] Stanford Univ, Dept Med, Sch Med, Div Oncol, Stanford, CA 94305 USA

[2] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA

[5] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[6] Univ Hosp Birmingham, Dept Dermatol, Birmingham, W Midlands, England

[7] Univ Turin, Dept Med Sci, Turin, Italy

[8] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[9] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[10] Seattle Genet Inc, Seattle, WA USA

[11] Takeda Pharmaceut, Cambridge, MA 02138 USA

[12] Peter MacCallum Canc Ctr, Canc Med, Melbourne, Vic, Australia

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.182.182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

182

引用

页数：8

共 42 条

[1] Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
Kim, Y. H.
Whittaker, S.
Horwitz, S. M.
Duvic, M.
Dummer, R.
Scarisbrick, J.
Quaglino, P.
Zinzani, P.
Wolter, P.
Wang, Y.
Palanca-Wessels, M.
Zagadailov, E.
Trepicchio, W. L.
Lin, H.
Little, M.
Prince, H.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S45 - S45
[2] PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN'S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL): NUMBER NEEDED TO TREAT ANALYSIS
Zagadailov, E.
Prince, H. M.
Whittaker, S.
Horwitz, S.
Duvic, M.
Kim, Y.
Dummer, R.
Scarisbrick, J.
Quaglino, P.
Zinzani, P. L.
Wolter, P.
Geskin, L.
Feliciano, J.
Wang, Y.
Palanca-Wessels, M. C.
Gautam, A.
Zhu, Y.
Lin, H. -M.
Liu, Y.
Little, M.
Dalal, M. R.
HAEMATOLOGICA, 2017, 102 : 251 - 251
[3] Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Horwitz, Steven M.
Scarisbrick, Julia J.
Dummer, Reinhard
Whittaker, Sean
Duvic, Madeleine
Kim, Youn H.
Quaglino, Pietro
Zinzani, Pier Luigi
Bechter, Oliver
Eradat, Herbert
Pinter-Brown, Lauren
Akilov, Oleg E.
Geskin, Larisa
Sanches, Jose A.
Ortiz-Romero, Pablo L.
Weichenthal, Michael
Fisher, David C.
Walewski, Jan
Trotman, Judith
Taylor, Kerry
Dalle, Stephane
Stadler, Rudolf
Lisano, Julie
Bunn, Veronica
Little, Meredith
Prince, H. Miles
BLOOD ADVANCES, 2021, 5 (23) : 5098 - 5106
[4] Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada
David Elsea
Kerry J. Savage
Cameron Lilley
Julie Lisano
Jingmin Liu
Kristina S. Yu
Advances in Therapy, 2023, 40 : 2326 - 2338
[5] Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada
Elsea, David
Savage, Kerry J.
Lilley, Cameron
Lisano, Julie
Liu, Jingmin
Yu, Kristina S.
ADVANCES IN THERAPY, 2023, 40 (05) : 2326 - 2338
[6] Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study
Kim, Youn H.
Prince, H. Miles
Whittaker, Sean
Horwitz, Steven M.
Duvic, Madeleine
Bechter, Oliver
Sanches, Jose A.
Stadler, Rudolf
Scarisbrick, Julia
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Eradat, Herbert
Pinter-Brown, Lauren C.
Ortiz-Romero, Pablo L.
Akilov, Oleg E.
Trotman, Judith
Taylor, Kerry
Weichenthal, Michael
Walewski, Jan
Fisher, David C.
McNeeley, Marise
Gru, Alejandro A.
Wang, Yinghui
Palanca-Wessels, Maria Corinna
Lisano, Julie
Li, Martha
Lin, Hui-Min
Little, Meredith
Trepicchio, William L.
Dummer, Reinhard
BLOOD, 2018, 132
[7] Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 14 - 15
[8] Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (By) vs physician's choice (PC) in the Phase 3 ALCANZA study.
Kim, Youn H.
Prince, H. Miles
Whittaker, Sean
Horwitz, Steven M.
Duvic, Madeleine
Scarisbrick, Julia
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Bechter, Oliver
Wang, Yinghui
Corinna, Maria
Wessels, Palanca
Wood, Kenneth W.
Li, Martha
Liu, Vi
Lin, Hui-Min
Little, Meredith
Danaee, Hadi
Trepicchio, William L.
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Prince, H. Miles
Kim, Youn H.
Horwitz, Steven M.
Dummer, Reinhard
Scarisbrick, Julia
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Sanches, Jose A.
Ortiz-Romero, Pablo L.
Akilov, Oleg E.
Geskin, Larisa
Trotman, Judith
Taylor, Kerry
Dalle, Stephane
Weichenthal, Michael
Walewski, Jan
Fisher, David
Dreno, Brigitte
Stadler, Rudolf
Feldman, Tatyana
Kuzel, Timothy M.
Wang, Yinghui
Palanca-Wessels, Maria Corinna
Zagadailov, Erin
Trepicchio, William L.
Zhang, Wenwen
Lin, Hui-Min
Liu, Yi
Huebner, Dirk
Little, Meredith
Whittaker, Sean
Duvic, Madeleine
LANCET, 2017, 390 (10094): : 555 - 566
[10] Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Scarisbrick, Julia
Horwitz, Steven M.
Prince, H. Miles
Whittaker, Sean
Duvic, Madeleine
Kim, Youn H.
Quaglino, Pietro
Zinzani, Pier Luigi
Bechter, Oliver
Eradat, Herbert
Pinter-Brown, Lauren
Akilov, Oleg
Geskin, Larisa
Sanches, Jose
Ortiz-Romero, Pablo
Lisano, Julie
Brown, Lisa
Bunn, Veronica
Little, Meredith
Dummer, Reinhard
EUROPEAN JOURNAL OF CANCER, 2019, 119 : S31 - S31

← 1 2 3 4 5 →